A wireless, three-centimeter implant that converts blood sugar into a flushable compound successfully lowered elevated glucose levels in mice within 60 to 90 minutes of activation, according to research published in Science.
How the Wireless Catalyst Clears Glucose
The under-the-skin device operates without drugs, added genes, or living cells. It features a catalyst made of gold flakes and platinum particles layered on spongelike graphite. Powered by electricity, this catalyst turns excess glucose into gluconate, a compound the kidneys easily clear through urine. Martin Fussenegger, a bioengineer at ETH Zurich, explains that the system targets the root energy surplus caused by glucose.
“This system kind of targets the root cause, which is the energy surplus by glucose in the body,” said Martin Fussenegger, a bioengineer at ETH Zurich.
An automated setup links the implant to a wearable continuous glucose monitor and a smartphone. When blood sugar rises, the phone switches the implant on, and it shuts off automatically once levels normalize. This closed-loop system ran for two weeks across eight test mice. While the catalyst endured three months under the skin in laboratory testing, the overall operational lifespan of the entire hardware remains unverified.
Decoding the Metabolic Shift in Mice
After six weeks of treatment, the mice shed up to 10 percent of their body weight. Their blood profiles also showed lower triglycerides, which are fats circulating in the bloodstream. Because the body had less available glucose for energy, it shifted toward burning fat stores instead. Researchers observed elevated levels of ketones, chemical byproducts released during fat breakdown.
Existing diabetes management tools require strict dosing regimens for insulin or GLP-1 receptor agonists. Other experimental implants still depend on insulin to clear sugar rather than removing it entirely from the body. Scaling up the hardware poses distinct engineering hurdles for future human translation. Humans consume roughly 250 grams of carbohydrates daily, whereas the mice in the study consumed only two grams.
Risks of Gluconate Accumulation and Electrolyte Depletion
David Klonoff, an endocrinologist at Sutter Mills-Peninsula Medical Center in Burlingame, California, who was not involved with the study, points out that significant risks require careful evaluation before human trials begin.
Researchers must establish how much gluconate human kidneys can process without adverse events. If gluconate accumulates, it can disrupt the body’s acid-base balance and trigger symptoms like confusion or nausea. Excreting the compound could deplete vital electrolytes such as potassium and sodium.
“But the risks are significant and must be carefully ruled out before it can be safely tested on humans,” said David Klonoff, an endocrinologist at Sutter Mills-Peninsula Medical Center in Burlingame, California.
Patients managing type 2 diabetes or obesity should not alter current treatment protocols, medication dosages, or dietary habits based on preclinical animal models. Anyone experiencing erratic blood glucose readings, severe metabolic symptoms, or signs of diabetic ketoacidosis must seek immediate medical evaluation from a qualified physician or endocrinologist.
Fussenegger’s research team plans to evaluate the device in larger animal models, specifically pigs and sheep, before seeking regulatory approval for human clinical trials.
David Klonoff notes that bridging the volumetric gap between rodent and human blood volume requires building substantially larger implants or deploying multiple units simultaneously. Lab tests on a five-liter solution—roughly equivalent to an adult human blood volume—demonstrated that a scaled-up prototype could clear nearly all dissolved glucose.
If subsequent preclinical data confirm both safety and efficacy, the technology could introduce an alternative therapeutic avenue for metabolic conditions. Fussenegger suggests the hardware could eventually function as a weight-loss intervention for individuals regardless of a formal diabetes diagnosis.
